Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report

Creative Commons License

Demiral A., Yerebakan O., şimşir v., Alpsoy E.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.32, sa.11, ss.477-479, 2002 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 11
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1093/jjco/hyf095
  • Dergi Adı: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.477-479
  • Anahtar Kelimeler: amifostine, toxic epidermal necrolysis, radiotherapy, STEVENS-JOHNSON-SYNDROME, NECK-CANCER, ERYTHEMA MULTIFORME, HEAD, RADIOCHEMOTHERAPY, CYTOPROTECTION, RADIOPROTECTOR, IRRADIATION
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Amifostine is a phosphorylated aminothiol prodrug that can selectively protect normal tissues against the toxic effects of chemotherapy and radiotherapy. In clinical use amifostine is well tolerated and may rarely cause allergic reactions. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are two closely related entities that present with severe acute mucocutaneous reactions most often triggered by drugs. There are only two case reports related to the use of amifostine during radiotherapy, one case with SJS and the other with SJS-TEN overlap. In this paper, a case with amifostine-induced TEN during radiotherapy is presented.